Aa
Desperate to build AntiHBs
hbsag +
anti hbs neg
hbeag neg
anti hbe +
alt and ast normal since 2005
hbv dna less than 116 copies / ml ( undetectable ) 2012
HBsAg quantitaive from 19 IU/ml to 13.4 IU/ml then 16 IU/ml and then 20.23 IU over last 18 months
Started with
-PEG interferon 180 mcg once weekly
-Vit D
after 5 inj and ALT 103 which had always been previously normal
After 11 inj ALT 70 and HBsAg 18 IU/ml
After 23 inj peg Alt is 42 and HBsAg is 0.21 IU/ml quantitative
09 months on pegasys ALt 42 , HBsAg 0.05 IU/ml, AntiHBs 5.6
10 months on PEGasys....HBsAg quantitative 0.03 IU/ml
Anti HBs 6.22
12 months on pegasys antihbs 6.24 and vit D 32
got engerix b
13 months 2nd engerix b and HBsAg by ELISA negative
14 months on pegasys anti hbs 4.83 and vit D 95
tough fight going on ....
desperate to build antibodies after HBsAg quantitative 0.03 IU/ml and HBsAg negative by ELISA
instead of increase, antiHBs has decreased to 4.83 from 6.24
What should i do next ??
Continue with Pegasys ??
anti hbs neg
hbeag neg
anti hbe +
alt and ast normal since 2005
hbv dna less than 116 copies / ml ( undetectable ) 2012
HBsAg quantitaive from 19 IU/ml to 13.4 IU/ml then 16 IU/ml and then 20.23 IU over last 18 months
Started with
-PEG interferon 180 mcg once weekly
-Vit D
after 5 inj and ALT 103 which had always been previously normal
After 11 inj ALT 70 and HBsAg 18 IU/ml
After 23 inj peg Alt is 42 and HBsAg is 0.21 IU/ml quantitative
09 months on pegasys ALt 42 , HBsAg 0.05 IU/ml, AntiHBs 5.6
10 months on PEGasys....HBsAg quantitative 0.03 IU/ml
Anti HBs 6.22
12 months on pegasys antihbs 6.24 and vit D 32
got engerix b
13 months 2nd engerix b and HBsAg by ELISA negative
14 months on pegasys anti hbs 4.83 and vit D 95
tough fight going on ....
desperate to build antibodies after HBsAg quantitative 0.03 IU/ml and HBsAg negative by ELISA
instead of increase, antiHBs has decreased to 4.83 from 6.24
What should i do next ??
Continue with Pegasys ??
Best Answer
Try to have multiple advice from different docs and try to do like safi with black seeds to improve your immune system
yet to see him
I think he ll give me option to stop Pegasys and observe
as he did the last time
Any how i ll see him soon
I think he ll give me option to stop Pegasys and observe
as he did the last time
Any how i ll see him soon
Here is the long awaited result of the Cuban surface antigen plus core particle vaccine study, mucosal and subcutaneous. It looks fairly promising.
TITLE: A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B
AUTHORS (FIRST NAME, LAST NAME): Sheikh Mohammad Fazle Akbar1, 4, Mamun A. Mahtab2, Salimur Rahman2, Julio Cesar Aguilar3, Yoichi Hiasa4, Shunji Mishiro1
Institutional Author(s):
INSTITUTIONS (ALL): 1. Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan.
2. Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
3. Clinical Trials , Center for Genetic Engineering and Biotechnology, Havana, Cuba.
4. Department of Gastroenetrology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
ABSTRACT BODY: Background and aims: Lack of information is prevailing about scope and limitation of a therapeutic vaccine for chronic hepatitis B (1) that utilized multiple antigens; both HBsAg and HBcAg, (2) applied via multiple routes of administration: both mucosal and parenteral, and (3) conducted as a phase III clinical trial in same run in which a different arm received an established and commercially-available antiviral drug. Methods: A total of 160 patients with clinical, biochemical, and virological evidences of chronic hepatitis B were enrolled in a phase III clinical trial (Clinical Trials.Gov identifier NCT01374308) after receiving written consent of the patients and written permission of institutional review board (Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh). The patients were randomly assigned to receive either a therapeutic vaccine (HBsAg/HBcAg-based vaccine) or pegylated interferon (Peg-IFN). Seventy-five CHB patients completed the therapeutic schedule of immunization with
100 microgram of both HBsAg and HBcAg (HBsAg/HBcAg) (Center for Genetic Engineering and Biotechnology, Havana, Cuba), once in every two weeks (5 vaccinations through only nasal route and followed by 5 additional vaccinations via both nasal and subcutaneous route).
Seventy-six patients with CHB completed the treatment with Peg IFN (180 microgram, once weekly, subcutaneously for 48 consecutive weeks). Parameters of safety and therapeutic efficacy were checked during treatment period and also for 24 weeks after end of treatment (EOT).
Results: Preliminary results evidenced the safety of HBsAg/HBcAg-based therapeutic immunization; no serious or severe adverse event was detected. Forty-six of 75 patients (61%) receiving HBsAg/HBcAg vaccine reduced the HBV DNA below 250 copies/ml (undetectable HBV DNA) at EOT and a similar proportion remain below 250 copies/mL at the end of 24 weeks of treatment-free follow up. Fifty-one of 76 patients (67%) receiving Peg-IFN reduced the HBV DNA level below 250 copies/mL at EOT, however, only 39% remain under the same level at 24 weeks after EOT during treatment-free follow up. ALT increases were not clinically symptomatic in patients receiving HBsAg/HBcAg vaccine and a generalized normalization of ALT values in the majority of patients at the EOT and 24 weeks of treatment-free follow up was recorded. Conclusions: A therapeutic vaccine therapy containing HBsAg/HBcAg represents a safe and efficacious therapeutic approach for CHB. This study inspired optimism that ongoing protocols of immune therapy against CHB may be improved by altering nature of antigens and route of administration.
TITLE: A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B
AUTHORS (FIRST NAME, LAST NAME): Sheikh Mohammad Fazle Akbar1, 4, Mamun A. Mahtab2, Salimur Rahman2, Julio Cesar Aguilar3, Yoichi Hiasa4, Shunji Mishiro1
Institutional Author(s):
INSTITUTIONS (ALL): 1. Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan.
2. Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
3. Clinical Trials , Center for Genetic Engineering and Biotechnology, Havana, Cuba.
4. Department of Gastroenetrology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
ABSTRACT BODY: Background and aims: Lack of information is prevailing about scope and limitation of a therapeutic vaccine for chronic hepatitis B (1) that utilized multiple antigens; both HBsAg and HBcAg, (2) applied via multiple routes of administration: both mucosal and parenteral, and (3) conducted as a phase III clinical trial in same run in which a different arm received an established and commercially-available antiviral drug. Methods: A total of 160 patients with clinical, biochemical, and virological evidences of chronic hepatitis B were enrolled in a phase III clinical trial (Clinical Trials.Gov identifier NCT01374308) after receiving written consent of the patients and written permission of institutional review board (Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh). The patients were randomly assigned to receive either a therapeutic vaccine (HBsAg/HBcAg-based vaccine) or pegylated interferon (Peg-IFN). Seventy-five CHB patients completed the therapeutic schedule of immunization with
100 microgram of both HBsAg and HBcAg (HBsAg/HBcAg) (Center for Genetic Engineering and Biotechnology, Havana, Cuba), once in every two weeks (5 vaccinations through only nasal route and followed by 5 additional vaccinations via both nasal and subcutaneous route).
Seventy-six patients with CHB completed the treatment with Peg IFN (180 microgram, once weekly, subcutaneously for 48 consecutive weeks). Parameters of safety and therapeutic efficacy were checked during treatment period and also for 24 weeks after end of treatment (EOT).
Results: Preliminary results evidenced the safety of HBsAg/HBcAg-based therapeutic immunization; no serious or severe adverse event was detected. Forty-six of 75 patients (61%) receiving HBsAg/HBcAg vaccine reduced the HBV DNA below 250 copies/ml (undetectable HBV DNA) at EOT and a similar proportion remain below 250 copies/mL at the end of 24 weeks of treatment-free follow up. Fifty-one of 76 patients (67%) receiving Peg-IFN reduced the HBV DNA level below 250 copies/mL at EOT, however, only 39% remain under the same level at 24 weeks after EOT during treatment-free follow up. ALT increases were not clinically symptomatic in patients receiving HBsAg/HBcAg vaccine and a generalized normalization of ALT values in the majority of patients at the EOT and 24 weeks of treatment-free follow up was recorded. Conclusions: A therapeutic vaccine therapy containing HBsAg/HBcAg represents a safe and efficacious therapeutic approach for CHB. This study inspired optimism that ongoing protocols of immune therapy against CHB may be improved by altering nature of antigens and route of administration.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
If possible use the Israeli scigen triple antigen vaccine.
Use Aldara cream on the skin of the shoulder before ...2 hour..and again at the time of intradermal placement of the vaccine, you can use half the dose this way. Use at least 10 tiny injections approx 50ul so the vaccine does not flow back out.
Use 2 times 1.6mg thymosin alpha per week for at least 8 weeks, inject sc at the same time as the vaccination and at the same place. Thymosin alpha is available in many countries. Check the sciclone website.
Your doctor can also try to obtain full length core particles and mix them with the vaccine. 10ug per vaccination should be sufficient. Should be allowed to aggregate with the hbsag particles for at least 2 hours before use. You can bring your doctor the paper in the journal nature about the details of the mixed surface antigen and core vaccine by the Cuban vaccine development center. The results of the combined intranasal and parentral use of this mix in chronic HBV patients were also published in the 2013 AASLD abstracts. They were much better than any other therapeutic vaccine trial before.ABIVAX is now pursuing the further development of this combo vaccine.
Discuss and coordinate everything with your doctor.